DiaMedica Therapeutics Files 8-K
Ticker: DMAC · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1401040
| Field | Detail |
|---|---|
| Company | Diamedica Therapeutics Inc. (DMAC) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
Related Tickers: DMAC
TL;DR
DiaMedica filed a routine 8-K, no major news.
AI Summary
DiaMedica Therapeutics Inc. filed an 8-K on July 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this date.
Why It Matters
This 8-K filing indicates routine corporate reporting by DiaMedica Therapeutics Inc. to the SEC, without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain information that suggests a change in risk for the company.
Key Players & Entities
- DiaMedica Therapeutics Inc. (company) — Registrant
- July 17, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits as of July 17, 2025.
What is the exact name of the registrant?
The exact name of the registrant is DiaMedica Therapeutics Inc.
In which jurisdiction was DiaMedica Therapeutics Inc. incorporated?
DiaMedica Therapeutics Inc. was incorporated in British Columbia, Canada.
What is the principal executive office address for DiaMedica Therapeutics Inc.?
The principal executive office address is 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305.
What is the telephone number for DiaMedica Therapeutics Inc.?
The telephone number for DiaMedica Therapeutics Inc. is (763) 496-5454.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding DiaMedica Therapeutics Inc. (DMAC).